Early Detection Means More Life

The 5-year survival rate for many cancers is almost 90% when detected early (1).

Discover the difference

Cancer Check is the clear choice when selecting an early cancer detection screen.

How it worksWhy it works
Other blood tests (Liquid Biopsies)
Full Body Scans
Cancer Specific Tests
Feature Category
Early Detection of Cancers
Detects Multiple Cancers
Minimally Invasive
25
Unlimited
Unlimited
Unlimited
Accuracy
In-home Convenience
Reliability
Cancer Screening as early as Stage 0.
Screen for 200+ types and subtypes of solid cancer tumors
We find COMPLETE circulating tumor cells. A circulating tumor cell (CTC) is a cancer cell that has detached from primary tumor and entered the bloodstream. These cells are considered "circulating" because they move through the bloodstream and can spread cancer to other parts of the body. CTCs begin shedding at stage 0 enabling very early detection.
Our test uses gold-standard tissue staining techniques (H&E and IHC) that have been standard of care usage for DECADES by pathologists. We don't guess - we look at actual cellular tissue.
Each test is reviewed by human board-certified pathologists.
Board-certified pathological tissue biopsy report issued with every test.
Simple blood draw from the convenience of home or location of your choice.
$1,995
Other Cancer Blood Tests
Have a very low probability of catching cancer in stages 0, 1, and 2.
Screens for only a handful of cancer types. Some cheap tests only screen for 5 or 6 biomarkers.
Analyze bits and pieces of cells and extrapolates if a cancer is present. This can mean worrisome false positives and unnecessary costly and dangerous interventions or potentially fatal false negatives.
Use complex algorithms with no transparency to make predictions, which can sometimes lead to innacurate results.
No tissue sample for medical professional to review
No tissue biopsy report
Blood draw
$199 - 2,000
Full Body Scans
Have a very low probabilities of catching cancer in stages 0 and 1.
Primarily focused on structural issues; not designed for early cancer detection.
Less specific for cancer detection; focuses on structural abnormalities.
Can't use gold-standard cancer detection techniques because they don't collect tissue or cellular tissue.
No tissue sample for medical professional to review
No tissue biopsy report
Requires lengthy imaging, sometimes with radiation exposure.
$999 - $4,500+
Cancer-Specific Tests
Limited screen options for most cancer types.
Focuses on one area for cancer instead of whole-body detection
Cannot accurately screen for most cancer types.
No pan-cancer screening capability.
Some have a tissue sample, but for only one cancer location.
Some have a tissue sample, but for only one cancer location.
May require surgically invasive procedures, imaging, blood tests, anesthesia, stool samples, etc.
Wide range from hundreds to thousands of dollars, depending on the screen.

Convenience and Reliability

Cancer has a 98% survival rate when detected at Stage 0 (2). Since early detection saves lives, we make sure Cancer Check's screen is easy and dependable.

Reliable Results

Our test can catch circulating tumor cells as early as Stage 0.

In-Home/Office Phlebotomy Appointments

No need to travel for blood draws – we bring the lab to you.

Whole Body Biopsy Screening

Screen for more than 200 types and sub-types of solid tumor cancers with unmatched accuracy.

Investment in Tomorrow

Early screening means proactive management of potential issues for a longer, healthier life.

The Impact of Cancer On Our Lives

Early detection leads to better outcomes. Let's work together to improve these statistics.

Men
Women
Estimated New Cases
Prostate
299,010
29%
Lung & Bronchus
116,310
11%
Colon & Rectum
81,540
8%
Urinary Bladder
63,070
6%
Melanoma of the Skin
59,170
6%
Kidney & Renal Pelvis
52,380
5%
Non-Hodgkin’s Lymphoma
44,590
4%
Oral Cavity & Pharynx
44,590
4%
Leukemia
36,450
4%
Pancreas
34,530
3%
All Sites
1,029,080
Lung & Bronchus
65,790
20%
Prostate
35,250
11%
Colon & Rectum
28,700
9%
Pancreas
27,270
8%
Liver & Intrahepatic Bile Duct
19,120
6%
Leukemia
13,640
4%
Esophagus
12,880
4%
Urinary Bladder
12,290
4%
Non-Hodgkin’s Lymphoma
11,780
4%
Brain & Other Nervous System
10,690
3%
All Sites
322,800
Estimated Deaths
Breast
310,720
32%
Lung & Bronchus
118,270
12%
Colon & Rectum
71,270
7%
Uterine Corpus
67,880
7%
Melanoma of the Skin
41,470
4%
Non-Hodgkin’s Lymphoma
36,030
4%
Pancreas
31,910
3%
Thyroid
31,520
3%
Kidney & Renal Pelvis
29,230
3%
Leukemia
26,320
3%
All Sites
972,060
Estimated New Cases
Lung & Bronchus
59,280
21%
Breast
42,250
15%
Pancreas
24,480
8%
Colon & Rectum
24,310
8%
Uterine Corpus
13,250
5%
Ovary
12,740
4%
Liver & Intrahepatic Bile Duct
10,720
4%
Leukemia
10,030
3%
Non-Hodgkin’s Lymphoma
8,360
3%
Brain & Other Nervous System
8,070
3%
All Sites
288,920
Estimated Deaths

Estimates are rounded to the nearest 10, and cases exclude basal cell and squamous cell skin cancer and in situ carcinoma except urinary bladder. Estimates do not include Puerto Rico or other US territories. Ranking is based on modeled projections and may differ from the most recent observed data.
(c) 2024, American Cancer Society, Inc., Surveillance and Health Equity Science

Screen with Cancer Check and enjoy life's most precious.

Screen Today
For More Tomorrows

Continue